Evidence map›Paper›PMID 35249577›Full record

ArticleEpidemiology and infection2021

Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019.

Anna Lee Wilkinson, Alisa Pedrana, Michael W Traeger, Jason Asselin, Carol El-Hayek, Long Nguyen, Victoria Polkinghorne, Joseph S Doyle, Alexander J Thompson, Jessica Howell and 6 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Epidemiology and infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Anna Lee WilkinsonDisease Elimination Program, Burnet Institute, Melbourne, Australia.ORCID 0000-0002-4475-5224
Alisa PedranaDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Michael W TraegerDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Jason AsselinDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Carol El-HayekDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Long NguyenDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Victoria PolkinghorneDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Joseph S DoyleDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Alexander J ThompsonDepartment of Gastroenterology, St Vincent's Hospital, Melbourne, Australia.
Jessica HowellDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Nick ScottDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Wayne DimechNational Serology Reference Laboratory, Melbourne, Australia.
Rebecca GuyKirby Institute, UNSW, Sydney, Australia.
Margaret HellardDisease Elimination Program, Burnet Institute, Melbourne, Australia.
Mark StoovéDisease Elimination Program, Burnet Institute, Melbourne, Australia.
EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of blood-borne viruses AND sexually transmissible infections (ACCESS)
Burnet Institute · AUThe University of Melbourne · AUUNSW Sydney · AUVictorian Infectious Diseases Reference Laboratory · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To achieve the elimination of the hepatitis C virus (HCV), sustained and sufficient levels of HCV testing is critical. The purpose of this study was to assess trends in testing and evaluate the effectiveness of strategies to diagnose people living with HCV. Data were from 12 primary care clinics in Victoria, Australia, that provide targeted services to people who inject drugs (PWID), alongside general health care. This ecological study spanned 2009-2019 and included analyses of trends in annual numbers of HCV antibody tests among individuals with no previous positive HCV antibody test recorded and annual test yield (positive HCV antibody tests/all HCV antibody tests). Generalised linear models estimated the association between count outcomes (HCV antibody tests and positive HCV antibody tests) and time, and χ2 test assessed the trend in test yield. A total of 44 889 HCV antibody tests were conducted 2009-2019; test numbers increased 6% annually on average [95% confidence interval (CI) 4-9]. Test yield declined from 2009 (21%) to 2019 (9%) (χ2P = <0.01). In more recent years (2013-2019) annual test yield remained relatively stable. Modest increases in HCV antibody testing and stable but high test yield within clinics delivering services to PWID highlights testing strategies are resulting in people are being diagnosed however further increases in the testing of people at risk of HCV or living with HCV may be needed to reach Australia's HCV elimination goals.

Indexed as

Hepatitis CSubstance Abuse, IntravenousAntiviral AgentsHepacivirusHumansPrimary Health CareSentinel SurveillanceVictoriaAntiviral AgentsHepatitis Cpeople who inject drugsprimary caresurveillance

Identifiers

PMID35249577
PMCPMC8753485
OpenAlexW4200060680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.